Tillman Hartley LLC Has $542,000 Stock Position in Eli Lilly and Company $LLY

Tillman Hartley LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 15.4% in the 2nd quarter, Holdings Channel reports. The firm owned 695 shares of the company’s stock after buying an additional 93 shares during the quarter. Tillman Hartley LLC’s holdings in Eli Lilly and Company were worth $542,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Blume Capital Management Inc. lifted its holdings in Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the last quarter. IMG Wealth Management Inc. bought a new stake in Eli Lilly and Company during the second quarter worth approximately $35,000. TD Capital Management LLC grew its holdings in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares during the last quarter. Finally, Family CFO Inc bought a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $54,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $923.35 on Monday. The firm has a market cap of $872.92 billion, a P/E ratio of 60.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The firm’s 50-day simple moving average is $799.97 and its 200-day simple moving average is $775.01. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $955.46. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. JPMorgan Chase & Co. cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $983.76.

Insider Buying and Selling

In other news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 4,314 shares of company stock valued at $2,766,929. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.